



Adoram Therapeutics Secures Pre-Seed Investment to Advance Innovative Cancer Immunotherapy and Inflammation Programs

Geneva, Switzerland, 25.02.2025,

Adoram Therapeutics, a Swiss-based biotech company spun off from the University of Geneva, specializing in allosteric modulators for cancer immunotherapy and inflammatory conditions, is excited to announce that it has secured a pre-seed investment to accelerate its groundbreaking research.

The pre-seed funding round was led by private business angels, Ipalmatrix, and FONGIT - the Geneva incubator. This investment will enable Adoram Therapeutics to accelerate the development of its novel small molecule drugs designed to enhance the immune response in cancer patients and address multiple inflammation or autoimmune-related conditions.

"We are thrilled to receive this support as it significantly aids our efforts to bring innovative therapies to the clinic," said Dr. David PEJOSKI, co-CEO and co-founder of Adoram Therapeutics. He added, "Contributions and endorsement from private investors and FONGIT, empowers Adoram Therapeutics to advance to the next stage of growth and strengthens our position in the Swiss Biotech community. We wholeheartedly thank our investors for their trust in our vision to develop next-generation small molecule therapies for patients with unmet medical needs."

"This funding is a testament to the potential of our approach and the dedication of our team. It will be instrumental in getting our immune-oncology program closer to the clinic and consolidating the proof-of-concept studies of our anti-inflammatory asset. It will also enable the use of our differentiated platform to expand the pipeline in collaboration with co-development partners. We aim to continue discovering small molecule allosteric modulators for validated GPCR targets for patients in need of efficacious therapies" said Dr Hesham HAMED, co-CEO/CSO of Adoram Therapeutics.

Generous grants from the Swiss national innovation agency, Innosuisse, and the Geneva tech transfer office, UNITEC, allowed the conception of these ideas and the delivery of proof-of-concept studies in immuno-oncology and inflammation. The work done in the Pharmaceutical Biochemistry lab at University of Geneva led by Prof. Scapozza, laid the groundwork for the current advancements.

With this investment, Adoram Therapeutics aims to continue its mission of developing safer and more effective immunotherapies for patients with solid tumors and innovative treatments for inflammation-related diseases.

For more information, please visit www.adoram.ch

About Adoram Therapeutics: Adoram Therapeutics is a spin-off from the University of Geneva, focusing on the development of allosteric modulators to treat cancer and immune-based diseases. The company's innovative approach aims to overcome the limitations of previous drug generations and provide new solutions for patients in need.

Contact: info@aodram.ch